aldosterone has been researched along with Myocardial Ischemia in 22 studies
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aldosterone escape was defined as plasma levels of aldosterone above the normal range in our laboratory (> 0." | 5.31 | Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. ( Caruso, B; Cicoira, M; Franceschini, L; Golia, G; Rossi, A; Zanolla, L; Zardini, P; Zeni, P, 2002) |
| "Aldosterone blockade has been shown to reduce the incidence of sudden death in patients with heart failure." | 2.73 | Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. ( Donnan, PT; Pringle, SD; Shah, NC; Struthers, AD, 2007) |
| "Heart failure is associated with many comorbidities and among them, cancer has stood out as a contributor of death in these patients." | 2.72 | RAAS: A Convergent Player in Ischemic Heart Failure and Cancer. ( Cambrón-Mora, D; Garcia-Garduño, TC; Padilla-Gutierrez, JR; Valle, Y, 2021) |
| "Aldosterone promotes sodium and water retention, sympathoadrenergic activation, endothelial dysfunction, and cardiovascular fibrosis and hypertrophy." | 2.42 | Mineralocorticoid receptor antagonism and cardiac remodeling in ischemic heart failure. ( Bauersachs, J; Fraccarollo, D; Galuppo, P, 2004) |
| "Aldosterone production plays an important role in the remodeling of the heart." | 2.41 | Molecular mechanisms of myocardial remodeling. The role of aldosterone. ( Delcayre, C; Swynghedauw, B, 2002) |
| "Primary aldosteronism is the most frequent endocrine cause of secondary hypertension." | 1.42 | Primary aldosteronism and its various clinical scenarios. ( Abad-Cardiel, M; Alvarez-Alvarez, B; García-Donaire, JA; Martell-Claros, N; Pérez, CF, 2015) |
| "Aldosterone escape was defined as plasma levels of aldosterone above the normal range in our laboratory (> 0." | 1.31 | Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. ( Caruso, B; Cicoira, M; Franceschini, L; Golia, G; Rossi, A; Zanolla, L; Zardini, P; Zeni, P, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (18.18) | 18.2507 |
| 2000's | 15 (68.18) | 29.6817 |
| 2010's | 2 (9.09) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Garcia-Garduño, TC | 1 |
| Padilla-Gutierrez, JR | 1 |
| Cambrón-Mora, D | 1 |
| Valle, Y | 1 |
| Martell-Claros, N | 1 |
| Abad-Cardiel, M | 1 |
| Alvarez-Alvarez, B | 1 |
| García-Donaire, JA | 1 |
| Pérez, CF | 1 |
| Klotz, S | 1 |
| Burkhoff, D | 1 |
| Garrelds, IM | 2 |
| Boomsma, F | 1 |
| Danser, AH | 2 |
| Mill, JG | 1 |
| Stefanon, I | 1 |
| dos Santos, L | 1 |
| Baldo, MP | 1 |
| Delcayre, C | 1 |
| Swynghedauw, B | 1 |
| Strametz-Juranek, J | 1 |
| Pacher, R | 1 |
| Kos, T | 1 |
| Woloszczuk, W | 1 |
| Grimm, M | 1 |
| Zuckermann, A | 1 |
| Stanek, B | 1 |
| Huang, Y | 1 |
| Hunyor, SN | 1 |
| Jiang, L | 1 |
| Kawaguchi, O | 1 |
| Shirota, K | 1 |
| Ikeda, Y | 1 |
| Yuasa, T | 1 |
| Gallagher, G | 1 |
| Zeng, B | 1 |
| Zheng, X | 1 |
| Fraccarollo, D | 1 |
| Galuppo, P | 1 |
| Bauersachs, J | 1 |
| Weber, KT | 2 |
| Jaffe, IZ | 1 |
| Mendelsohn, ME | 1 |
| Fujita, M | 1 |
| Minamino, T | 1 |
| Asanuma, H | 1 |
| Sanada, S | 1 |
| Hirata, A | 1 |
| Wakeno, M | 1 |
| Myoishi, M | 1 |
| Okuda, H | 1 |
| Ogai, A | 1 |
| Okada, K | 1 |
| Tsukamoto, O | 1 |
| Koyama, H | 1 |
| Hori, M | 1 |
| Kitakaze, M | 1 |
| Wehling, M | 1 |
| Ishikawa, C | 1 |
| Tsutamoto, T | 1 |
| Wada, A | 1 |
| Fujii, M | 1 |
| Ohno, K | 1 |
| Sakai, H | 1 |
| Yamamoto, T | 1 |
| Horie, M | 1 |
| De Feo, S | 1 |
| Franceschini, L | 2 |
| Brighetti, G | 1 |
| Cicoira, M | 2 |
| Zanolla, L | 2 |
| Rossi, A | 2 |
| Golia, G | 2 |
| Zardini, P | 2 |
| Chai, W | 1 |
| de Vries, R | 1 |
| Shah, NC | 1 |
| Pringle, SD | 1 |
| Donnan, PT | 1 |
| Struthers, AD | 1 |
| Mitrovic, V | 1 |
| Oehm, E | 1 |
| Minge, C | 1 |
| Thürmann, P | 1 |
| Schlepper, M | 1 |
| Park, JW | 1 |
| Heinzler, R | 1 |
| Wirtz, JH | 1 |
| Fieten-Rumswinkel, M | 1 |
| Braun, P | 1 |
| May, E | 1 |
| Hetzer, R | 1 |
| Heinrich, KW | 1 |
| O'Leary, E | 1 |
| Hubbard, K | 1 |
| Tormey, W | 1 |
| Cunningham, AJ | 1 |
| Sun, Y | 1 |
| Cleutjens, JP | 1 |
| Guo, H | 1 |
| Lu, D | 1 |
| Wang, J | 1 |
| He, H | 1 |
| Zhou, B | 1 |
| Jiang, C | 1 |
| Zeni, P | 1 |
| Caruso, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| Evaluation of Low Pressure Pneumoperitoneum in Bariatric Surgery: A Prospective Randomized Study[NCT03179111] | 94 participants (Actual) | Interventional | 2017-08-30 | Completed | |||
| [NCT02324478] | 52 participants (Anticipated) | Observational | 2015-03-31 | Completed | |||
| Exercise Intolerance in Elderly Diastolic Heart Failure[NCT00123955] | Phase 3 | 80 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Left ventricle measurements by MRI:~Mass/end diastolic volume ratio: g/ml" (NCT00123955)
Timeframe: Baseline, 9 month
| Intervention | g/ml (Mean) | |
|---|---|---|
| baseline | 9 month | |
| Placebo | 1.7 | 1.6 |
| Spironolactone | 1.8 | 1.7 |
Peak exercise VO2 (NCT00123955)
Timeframe: Baseline, 4 and 9 months
| Intervention | ml/kg/min (Mean) | ||
|---|---|---|---|
| Baseline | 4 months | 9 months | |
| Placebo | 13.3 | 13.5 | 13.9 |
| Spironolactone | 13.5 | 13.6 | 13.8 |
"Echocardiography Doppler measurement of left ventricular diastolic function:~Early mitral annulus velocity (lateral) (Ea; cm/s)" (NCT00123955)
Timeframe: Baseline, 4 month and 9 month
| Intervention | cm/s (Mean) | ||
|---|---|---|---|
| baseline | 4 month | 9 month | |
| Placebo | 6.8 | 6.8 | 6.6 |
| Spironolactone | 7.0 | 7.0 | 7.4 |
"The Minnesota Living with Heart Failure Questionnaire (MLHF) is a self-administered disease-specific questionnaire for patients with Heart Failure, comprising 21 items rated on six-point Likert scales, representing different degrees of impact of HF on HRQoL, from 0 (none) to 5 (very much). It provides a total score (range 0-105, from best to worst HRQoL), as well as scores for two dimensions, physical (8 items, range 0-40) and emotional (5 items, range 0-25). The other eight items (of the total of 21) are only considered for the calculation of the total score.~Scale of 0-105:The higher the score the worse the heart failure related Quality of Life." (NCT00123955)
Timeframe: Baseline, 4 and 9 months
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 4 months | Final- 9 months | |
| Placebo | 28 | 29 | 25 |
| Spironolactone | 32 | 29 | 29 |
5 reviews available for aldosterone and Myocardial Ischemia
| Article | Year |
|---|---|
RAAS: A Convergent Player in Ischemic Heart Failure and Cancer.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Myocar | 2021 |
Remodeling in the ischemic heart: the stepwise progression for heart failure.
Topics: Adrenergic Neurons; Aldosterone; Angiotensins; Apoptosis; Arrhythmias, Cardiac; Heart; Heart Failure | 2011 |
Molecular mechanisms of myocardial remodeling. The role of aldosterone.
Topics: Aldosterone; Animals; Cardiomyopathies; Female; Fibrosis; Heart Failure; Humans; Mice; Mice, Transge | 2002 |
Mineralocorticoid receptor antagonism and cardiac remodeling in ischemic heart failure.
Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Ischemia; Myo | 2004 |
Structural remodeling of the infarcted rat heart.
Topics: Aldosterone; Angiotensin II; Animals; Collagen; Fibrosis; Humans; Metalloendopeptidases; Myocardial | 1996 |
3 trials available for aldosterone and Myocardial Ischemia
| Article | Year |
|---|---|
Inhibition of aldosterone and endothelin-1 by carperitide was attenuated with more than 1 week of infusion in patients with congestive heart failure.
Topics: Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Cardiomyopathy, Dilated; Chronic Disease; Cy | 2005 |
Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure.
Topics: Aged; Aldosterone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cross-Over Studies; Double-Blind Me | 2007 |
[Anti-ischemia effects of gallopamil and esmolol in an intra-individual comparison in patients with coronary heart disease].
Topics: Adrenergic beta-Antagonists; Aged; Aldosterone; Atrial Natriuretic Factor; Coronary Angiography; Cor | 1994 |
14 other studies available for aldosterone and Myocardial Ischemia
| Article | Year |
|---|---|
Primary aldosteronism and its various clinical scenarios.
Topics: Adult; Aged; Aldosterone; Cardiovascular Diseases; Female; Humans; Hyperaldosteronism; Hypertension; | 2015 |
The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences?
Topics: Adolescent; Adult; Aged; Aldosterone; Blood Pressure; Female; Heart Failure; Heart Transplantation; | 2009 |
Sequential big endothelin plasma levels in heart transplant recipients during bridging therapy and after successful heart transplantation.
Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Austria; Biomarkers; Blood Urea Nitrogen; Creatinine; | 2003 |
Remodeling of the chronic severely failing ischemic sheep heart after coronary microembolization: functional, energetic, structural, and cellular responses.
Topics: Aldosterone; Angiotensin II; Animals; Atrial Natriuretic Factor; Caspase 2; Caspase 3; Caspase 8; Ca | 2004 |
The neuroendocrine-immune interface gone awry in aldosteronism.
Topics: Aldosterone; Animals; Central Nervous System; Heart Failure; Humans; Hyperaldosteronism; Kidney; Min | 2004 |
Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Adenoviridae; Aldosterone; Angiotensin II; Angiotensin | 2005 |
Aldosterone nongenomically worsens ischemia via protein kinase C-dependent pathways in hypoperfused canine hearts.
Topics: Aldosterone; Animals; Coronary Circulation; Coronary Vessels; Dogs; Enzyme Activation; Heart; Hemody | 2005 |
Rapid effects of aldosterone: relevant in cardiac ischemia?
Topics: Aldosterone; Animals; Humans; Myocardial Ischemia; Time Factors | 2005 |
Ischemic etiology of heart failure identifies patients with more severely impaired exercise capacity.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Blood Flow Velocity; Blood Pressure; Echocardiography; | 2005 |
Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone?
Topics: Aldosterone; Animals; Cardiotonic Agents; Drug Interactions; Eplerenone; Heart; Hemodynamics; In Vit | 2006 |
Low-dose enoximone therapy in pre-transplant patients: hemodynamic, echocardiographic, and neurohumoral findings.
Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Combined Modality Therapy; Dose-Response Relationship | 1994 |
Laparoscopic cholecystectomy: haemodynamic and neuroendocrine responses after pneumoperitoneum and changes in position.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Cholecystectomy, Laparoscopic; Electrocardiography, Ambula | 1996 |
Laparoscopic cholecystectomy: haemodynamic and neuroendocrine responses after pneumoperitoneum and changes in position.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Cholecystectomy, Laparoscopic; Electrocardiography, Ambula | 1996 |
Laparoscopic cholecystectomy: haemodynamic and neuroendocrine responses after pneumoperitoneum and changes in position.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Cholecystectomy, Laparoscopic; Electrocardiography, Ambula | 1996 |
Laparoscopic cholecystectomy: haemodynamic and neuroendocrine responses after pneumoperitoneum and changes in position.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Cholecystectomy, Laparoscopic; Electrocardiography, Ambula | 1996 |
[Study on the relation between hypertensive left ventricular hypertrophy in very old people with neurohormonal factors and ventricular arrhythmias].
Topics: Aged; Aged, 80 and over; Aldosterone; Angiotensin II; Arrhythmias, Cardiac; Female; Humans; Hyperten | 2000 |
Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathy, Dilated; Chronic Diseas | 2002 |